Steven W. Lefkowitz - 26 Jan 2026 Form 4 Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: Director
Issuer ticker: CRMD
Reported as of: 26 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2026, 21:30:05 UTC
Prior SEC filing: 14 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Zelnick Kaufman, attorney-in-fact

Key filing fact

Steven W. Lefkowitz filed Form 4 for CorMedix Inc. (CRMD) on 27 Jan 2026.

Key facts

This page summarizes Steven W. Lefkowitz's Form 4 filing for CorMedix Inc. (CRMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Jan 2026, 21:30.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001313149 Primary reporting owner

Lefkowitz Steven W

Relationship: Director
Address: C/O CORMEDIX INC., 389 INTERPACE PKWY, SUITE 450, PARSIPPANY
Signature: /s/ Beth Zelnick Kaufman, attorney-in-fact
Signature date: 27 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRMD transaction

Common Stock

Award

Transaction value: $0
Shares: +30,453
Change %: +32%
Price: $0.000000
Shares after: 125,951
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1

CRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 30,152
Date: 26 Jan 2026
Ownership: Wade Capital Corporation Money Purchase Plan
Footnotes: F2

CRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,000
Date: 26 Jan 2026
Ownership: Reporting Person's Wife

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

Footnote F2

The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).